• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Kala Pharma wins FDA nod for twice-daily ocular corticosteroid

August 24, 2018 By Nancy Crotti

Kala PharmaceuticalsThe FDA has approved Kala Pharmaceuticals’ (NASDAQ:KALA) Inveltys to treat post-operative inflammation and pain following ocular surgery. Inveltys is the first twice-daily (BID) ocular corticosteroid approved for this indication, according to the Waltham, Mass. company.

While corticosteroids are used following ocular surgery to control inflammation and pain, physicians prescribe ocular steroids to achieve a rapid reduction of inflammation and to promote healing. All other ocular steroids are only approved for four-times-a-day dosing.

“The FDA approval of Inveltys is a tremendous milestone for Kala,” said Kim Brazzell, Kala’s chief medical officer, in a prepared statement. “Approximately 8 million patients undergo ocular surgeries each year. The approval of Inveltys offers patients and their eye care professionals the first and only BID ocular corticosteroid therapy that has been shown in clinical trials to be clinically effective while maintaining a proven safety profile, which may improve compliance and prove less burdensome for patients.”

“Today’s approval of Inveltys is welcome news for the eye care community as it provides a clear advancement in the treatment for inflammation and pain following ocular surgery,” said Dr. Terry Kim, chief of the cornea and external disease division at  Duke University Eye Center. “Having access to a BID corticosteroid in a novel nanoparticle formulation with proven safety and efficacy will make a positive impact on the management of my post-operative patients.”

Kala expects to launch Inveltys in early 2019 and plans to hire a specialty sales force for the drug in the U.S.

Kala has also begun a third Phase III clinical trial, Stride 3, for its dry-eye disease drug, KPI-121 . The company changed the design of Stride 3 after revealing mixed results from two Phase III trials in January.

The company expects to report top-line results for Stride 3 in the fourth quarter of 2019 and also plans to submit a new drug application for KPI-121 0.25% during the second half of 2018. The application will include data from three clinical trials studying approximately 2,000 patients, including one Phase II trial and two Phase III efficacy and safety trials (Stride 1 and Stride 2).

Kala’s shares dropped 6% yesterday following the Inveltys approval announcement. After closing at 12.51 per share, the stock was trading at 12.57 at midday today.

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Uncategorized Tagged With: FDA, Kala Pharmaceuticals

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS